New antibody drug targets Hard-to-Treat cancers in early trial
NCT ID NCT05482893
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called Spevatamig (PT886) in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The drug is a type of antibody that targets two proteins on cancer cells to help the immune system attack them. The trial will first find the safest dose, then test it alone or combined with chemotherapy or an immunotherapy drug. About 258 participants will take part to see if the drug is safe and shows signs of shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Spevatamig (PT886), a bispecific antibody targeting Claudin 18.2 and CD47, given alone or with chemotherapy (paclitaxel, gemcitabine, Abraxane) or an immune checkpoint inhibitor (pembrolizumab)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced stomach, pancreatic, or bile duct cancers that have not responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
RECRUITINGDuarte, California, 91010, United States
-
Dana-Farber Cancer Institute (DFCI)
ACTIVE_NOT_RECRUITINGBoston, Massachusetts, 02215, United States
-
Duke Cancer Center
RECRUITINGDurham, North Carolina, 27710, United States
-
MD Anderson Cancer Center, GI Medical Oncology Dept
RECRUITINGHouston, Texas, 77030, United States
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
-
Norton Cancer Institute
RECRUITINGLouisville, Kentucky, 40202, United States
-
Sarah Cannon Research Institute (SCRI)
RECRUITINGDenver, Colorado, 80218, United States
-
USC Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
-
University of Pittsburgh Medical Center (UPMC)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
RECRUITINGMadison, Wisconsin, 53792, United States